Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, 030001, China
NCT Number: NCT06870357
In an aging society, there is a surge in the number of surgeries for elderly patients in hospitals, and the elderly are at greater risk of anesthesia due to their own characteristics: slowing metabolism, decreasing resistance, and decreasing physical function, and increased sensitivity to propofol. However, there are large individual differences, and anesthesiologists have found that they cannot judge a patient's sensitivity to anesthetic drugs based on age alone. Patients with different levels of debilitation have different sensitivities to propofol. The use of measuring telomere length to assess the debilitating state of the elderly is a novel and reliable assessment method. Then the sensitivity to propofol of people with different debilitating states was studied, so as to guide anesthesiologists to use drugs safely and reasonably, with a view to realizing the purpose of precise anesthesia.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Early Phase 1
Taiyuan, Shanxi, 030001, China
Part I: A study of the correlation between telomere length and somatic debilitation status in older adults Telomere length was measured by fluorescent quantitative PCR, and subjects were assessed for somatic frailty using the Edmonton Scale (EFS).
Part II: Correlation between telomere length and propofol sensitivity in elderly surgical patients A total of 128 patients undergoing lower limb surgery under subarachnoid block in the Second Hospital of Shanxi Medical University were selected and divided into non-frailty group and frailty group.Propofol was pumped at a rate of 20 mg/kg/h with a micropump at 15 minutes after subarachnoid block, and the pumping rate was reduced to 10 mg/kg/h after 1 minute.Stop the infusion when consciousness is absent and observe the time of loss of consciousness (time of loss of eyelash reflex).
intraoperative recording of the time of loss of consciousness (time of disappearance of eyelash reflex), time of awakening, and dosage of propofol in both groups; recording of the time of admission to the room (T0), the time after completion of subarachnoid blockade (T1), the time after 1min of pumping propofol (T2), the time after 5min of pumping propofol (T3), the time after 10min of pumping propofol (T4), the time after 15min of pumping propofol ( T5), after pumping propofol for 20 min (T6), after pumping propofol for 25 min (T7), and after pumping propofol for 30 min (T8); mean arterial pressure (MAP), heart rate (HR), and electroencephalographic dual-frequency index (BIS value) at nine time points; the incidence of adverse reactions (hypotension, bradycardia, and respiratory depression) was recorded for the two groups.
Research hypotheses:
experimental procedure
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fifteen minutes after the subarachnoid block, propofol was pumped in at a rate of 20 mg/kg/h with a micro pump, and the pumping rate was reduced to 10 mg/kg/h after 1 min. The infusion was stopped when the consciousness disappeared, and the time of the disappearance of consciousness was observed (time of the disappearance of eyelash reflex).
Other names: Ropivacaine
Time frame: 24 hours
Differences in telomere length
Time frame: 24 hours
Differences in loss of consciousness time
Time frame: 24 hours
Differences in awakening time
Time frame: 24 hours
Differences in Propofol dosage
Time frame: 24 hours
Differences in Mean Arterial Pressure (MAP)
Time frame: 24 hours
Differences in heart rate
Time frame: 24 hours
Differences in Electroencephalographic dual frequency index (BIS value)
Time frame: 24 hours
Incidence of adverse effects (hypotension, bradycardia, respiratory depression)
Time frame: 24 hours
Use of vasoactive drugs
Time frame: 24 hours
Time frame: 24 hours
weight and height will be combined to report BMI in kg/m^2
Second Hospital of Shanxi Medical University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07580144
Atrophy, Frailty
Konya, Turkey (Türkiye)
View Trial DetailsNCT05629728
Frailty, Pathologic Processes
Daejeon, South Korea
View Trial DetailsNCT06576297
Aging, Frailty
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT05199857
Fontan Physiology, Frailty
Ann Arbor, Michigan, United States
View Trial Details